Nebenwirkungen · Jentadueto
Jentadueto 2.5 mg/850 mg film-coated tablets Jentadueto 2.5 mg/1 000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 10
HOS-214095 · Präparat HOS-155256
Linagliptin cardiovascular and renal safety study (CARMELINA) The CARMELINA study evaluated the cardiovascular and renal safety of linagliptin versus placebo in patients with type 2 diabetes and with increased CV risk evidenced by a history of established macrovascular or renal disease (see section 5.1). The study included 3 494 patients treated with linagliptin (5 mg) and 3 485 patients treated with placebo. Both treatments were added to standard of care targeting regional standards for HbA1c and CV risk factors. The overall incidence of adverse events and serious adverse events in patients receiving linagliptin was similar to that in patients
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-08T02:00:00Z · SHA-256 41f5c58f584e4cac6b69a3905358374a5edfffb09389cbadffe6f80383396210 · Passage 6278437127f6273d3d05076c6255684b469d88bde4a7c5d9f7ae554bb093a9d0 · Zeichen 6673–7325 im Abschnitt